Determining the age group-based cut-off values of serum anti-Mullerian hormone concentrations to diagnose polycystic ovary syndrome

References

• Chang RJ, Dumesic DA. Polycystic ovary syndrome and hyperandrogenic tates. In: Strauss JF, Barbieri RL, editors. Yen & Jaffe’s reproductive endocrinology: physiology, pathophysiology, and clinical management. 8th ed. Philadelphia (PA): Elsevier Inc.; 2019. p. 520–555.e13.
   Google Scholar
• Malgaigne M. Journal de Chırugıe [Internet]; 1844. Available from: https://books.google.com.tr/books?id=ERoUAAAAQAAJ.
   Google Scholar
• Stein IF, Leventhal ML. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol. 1935;29(2):181–191.
   Google Scholar
• Norman RJ, Dewailly D, Legro RS, et al. Polycystic ovary syndrome. Lancet. 2007;370(9588):685–697.
   PubMed Web of Science ®Google Scholar
• Fauser BCJM. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81(1):19–25.
   Web of Science ®Google Scholar
• Dewailly D, Pigny P, Soudan B, et al. Reconciling the definitions of polycystic ovary syndrome: the ovarian follicle number and serum anti-Müllerian hormone concentrations aggregate with the markers of hyperandrogenism. J Clin Endocrinol Metab. 2010;95(9):4399–4405.
   PubMed Web of Science ®Google Scholar
• Bell RJ, Islam RM, Skiba MA, et al. Substituting serum anti-Müllerian hormone for polycystic ovary morphology increases the number of women diagnosed with polycystic ovary syndrome: a community-based cross-sectional study. Hum Reprod. 2021;37(1):109–118.
   PubMed Web of Science ®Google Scholar
• Johnstone EB, Rosen MP, Neril R, et al. The polycystic ovary post-Rotterdam: a common, age-dependent finding in ovulatory women without metabolic significance. J Clin Endocrinol Metab. 2010;95(11):4965–4972.
   PubMed Web of Science ®Google Scholar
• Duijkers I, Klipping C. Polycystic ovaries, as defined by the 2003 Rotterdam consensus criteria, are found to be very common in young healthy women. Gynecol Endocrinol. 2010;26(3):1–9.
   PubMed Web of Science ®Google Scholar
• Balen A, Homburg R, Franks S. Defining polycystic ovary syndrome. BMJ. 2009;338(7692):a2968.
   PubMedGoogle Scholar
• Iliodromiti S, Kelsey TW, Anderson RA, et al. Can anti-Müllerian hormone predict the diagnosis of polycystic ovary syndrome? A systematic review and meta-analysis of extracted data. J Clin Endocrinol Metab. 2013;98(8):3332–3340.
   PubMed Web of Science ®Google Scholar
• Dewailly D, Gronier H, Poncelet E, et al. Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries. Hum Reprod. 2011;26(11):3123–3129.
   PubMed Web of Science ®Google Scholar
• Lauritsen MP, Bentzen JG, Pinborg A, et al. The prevalence of polycystic ovary syndrome in a normal population according to the Rotterdam criteria versus revised criteria including anti-Müllerian hormone. Hum Reprod. 2014;29(4):791–801.
   PubMed Web of Science ®Google Scholar
• Homburg R, Crawford G. The role of AMH in anovulation associated with PCOS: a hypothesis. Hum Reprod. 2014;29(6):1117–1121.
   PubMed Web of Science ®Google Scholar
• Visser JA, Themmen APN. Anti-Müllerian hormone and folliculogenesis. Mol Cell Endocrinol. 2005;234(1–2):81–86.
   PubMed Web of Science ®Google Scholar
• Teede H, Misso M, Tassone EC, et al. Anti-Müllerian hormone in PCOS: a review ınforming ınternational guidelines. Trends Endocrinol Metab. 2019;30(7):467–478.
   PubMed Web of Science ®Google Scholar
• Demirdjian G, Bord S, Lejeune C, et al. Performance characteristics of the access AMH assay for the quantitative determination of anti-Müllerian hormone (AMH) levels on the access* family of automated immunoassay systems. Clin Biochem. 2016;49(16–17):1267–1273.
   PubMed Web of Science ®Google Scholar
• Anckaert E, Öktem M, Thies A, et al. Multicenter analytical performance evaluation of a fully automated anti-Müllerian hormone assay and reference interval determination. Clin Biochem. 2016;49(3):260–267.
   PubMed Web of Science ®Google Scholar
• Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology. 1983;148(3):839–843.
   PubMed Web of Science ®Google Scholar
• Obuchowski NA, McClish DK. Sample size determination for diagnostic accuracy studies involving binormal ROC curve indices. Statist Med. 1997;16(13):1529–1542.
   PubMed Web of Science ®Google Scholar
• Balen AH, Laven JSE, Tan SL, et al. Ultrasound assessment of the polycystic ovary: ınternational consensus definitions. Hum Reprod Update. 2003;9(6):505–514.
   PubMed Web of Science ®Google Scholar
• Bentzen JG, Forman JL, Johannsen TH, et al. Ovarian antral follicle subclasses and anti-mullerian hormone during normal reproductive aging. J Clin Endocrinol Metab. 2013;98(4):1602–1611.
   PubMed Web of Science ®Google Scholar
• Lie Fong S, Laven JSE, Duhamel A, et al. Polycystic ovarian morphology and the diagnosis of polycystic ovary syndrome: redefining threshold levels for follicle count and serum anti-Müllerian hormone using cluster analysis. Hum Reprod. 2017;32(8):1723–1731.
   PubMed Web of Science ®Google Scholar
• Teede HJ, Misso ML, Costello MF, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril. 2018;110(3):364–379.
   PubMed Web of Science ®Google Scholar
• Dewailly D, Lujan ME, Carmina E, et al. Definition and significance of polycystic ovarian morphology: a task force report from the androgen excess and polycystic ovary syndrome society. Hum Reprod Update. 2014;20(3):334–352.
   PubMed Web of Science ®Google Scholar
• Bozdag G, Mumusoglu S, Zengin D, et al. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod. 2016;31(12):2841–2855.
   PubMed Web of Science ®Google Scholar
• Cela V, Obino MER, Alberga Y, et al. Ovarian response to controlled ovarian stimulation in women with different polycystic ovary syndrome phenotypes. Gynecol Endocrinol. 2018;34(6):518–523.
   PubMed Web of Science ®Google Scholar
• Namli Kalem M, Kalem Z, Gürgan T, et al. Problems and complications during the treatment of ınfertility in women with polycystic ovary syndrome. Gynecol Obstet Reprod Med. 2016;22(2):113–124.
   Google Scholar
• Sahmay S, Atakul N, Oncul M, et al. Serum anti-Mullerian hormone levels in the main phenotypes of polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2013;170(1):157–161.
   PubMed Web of Science ®Google Scholar
• Jamil AS, Alalaf SK, Al-Tawil NG, et al. Comparison of clinical and hormonal characteristics among four phenotypes of polycystic ovary syndrome based on the Rotterdam criteria. Arch Gynecol Obstet. 2016;293(2):447–456.
   PubMed Web of Science ®Google Scholar
• McCartney CR, Blank SK, Prendergast KA, et al. Obesity and sex steroid changes across puberty: evidence for marked hyperandrogenemia in pre- and early pubertal obese girls. J Clin Endocrinol Metab. 2007;92(2):430–436.
   PubMed Web of Science ®Google Scholar
• McCartney CR, Prendergast KA, Chhabra S, et al. The association of obesity and hyperandrogenemia during the pubertal transition in girls: obesity as a potential factor in the genesis of postpubertal hyperandrogenism. J Clin Endocrinol Metab. 2006;91(5):1714–1722.
   PubMed Web of Science ®Google Scholar
• Singer T, Barad DH, Weghofer A, et al. Correlation of antimüllerian hormone and baseline follicle-stimulating hormone levels. Fertil Steril. 2009;91(6):2616–2619.
   PubMed Web of Science ®Google Scholar
• Georgopoulos NA, Saltamavros AD, Decavalas G, et al. Serum AMH, FSH, and LH levels in PCOS. Fertil Steril. 2010;93(3):e13.
   PubMed Web of Science ®Google Scholar
• Willis D, Mason H, Gilling-Smith C, et al. Modulation by insulin of follicle-stimulating hormone and luteinizing hormone actions in human granulosa cells of normal and polycystic ovaries. J Clin Endocrinol Metab. 1996;81(1):302–309.
   PubMed Web of Science ®Google Scholar
• Cook CL, Siow Y, Brenner AG, et al. Relationship between serum müllerian-inhibiting substance and other reproductive hormones in untreated women with polycystic ovary syndrome and normal women. Fertil Steril. 2002;77(1):141–146.
   PubMed Web of Science ®Google Scholar
• Amer SAKS, Li TC, Bygrave C, et al. An evaluation of the inter-observer and intra-observer variability of the ultrasound diagnosis of polycystic ovaries. Hum Reprod. 2002;17(6):1616–1622.
   PubMed Web of Science ®Google Scholar
• Rao P, Bhide P. Controversies in the diagnosis of polycystic ovary syndrome. Ther Adv Reprod Heal. 2020;14:2633494120913032.
   Google Scholar
• Laven JSE, Mulders A, Visser JA, et al. Anti-Mullerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age. J Clin Endocrinol Metab. 2004;89(1):318–323.
   PubMed Web of Science ®Google Scholar
• Fu H, Lin Y, Deng X, et al. Correlation between anti-Mullerian hormone levels and antral follicle counts in polycystic ovary and metabolic syndromes. Syst Biol Reprod Med. 2021;67(2):112–120.
   PubMed Web of Science ®Google Scholar
• Elgun T, Karacan M, Sandal AI, et al. Can serum anti-Mullerian hormone level and LH/FSH ratio be predictive of clinical pregnancy through ıntracytoplasmic sperm Injection – embryo transfer? Gynecol Obstet Reprod Med. 2020;26(1):25–30.
   Google Scholar
• Tal R, Seifer DB. Potential mechanisms for racial and ethnic differences in antimullerian hormone and ovarian reserve. Int J Endocrinol. 2013;2013:818912.
   PubMed Web of Science ®Google Scholar
• Mahajan N, Kaur J. Establishing an Anti-Müllerian hormone cutoff for diagnosis of polycystic ovarian syndrome in women of reproductive age-bearing Indian ethnicity using the automated anti-Müllerian hormone assay. J Hum Reprod Sci. 2019;12(2):104–113.
   PubMedGoogle Scholar
• Li L, Chen X, Mo Y, et al. Elevated serum anti-mullerian hormone in adolescent and young adult Chinese patients with polycystic ovary syndrome. Wien Klin Wochenschr. 2010;122(17–18):519–524.
   PubMed Web of Science ®Google Scholar
• Dietz de Loos A, Hund M, Buck K, et al. Antimüllerian hormone to determine polycystic ovarian morphology. Fertil Steril. 2021;116(4):1149–1157.
   PubMed Web of Science ®Google Scholar
• Pigny P, Gorisse E, Ghulam A, et al. Comparative assessment of five serum antimullerian hormone assays for the diagnosis of polycystic ovary syndrome. Fertil Steril. 2016;105(4):1063–1069.e3.
   PubMed Web of Science ®Google Scholar
• Tremellen K, Zander-Fox D. Serum anti-Mullerian hormone assessment of ovarian reserve and polycystic ovary syndrome status over the reproductive lifespan. Aust N Z J Obstet Gynaecol. 2015;55(4):384–389.
   PubMed Web of Science ®Google Scholar
• Clark NM, Podolski AJ, Brooks ED, et al. Prevalence of polycystic ovary syndrome phenotypes using updated criteria for polycystic ovarian morphology . Reprod Sci. 2014;21(8):1034–1043.
   PubMed Web of Science ®Google Scholar
• Lizneva D, Kirubakaran R, Mykhalchenko K, et al. Phenotypes and body mass in women with polycystic ovary syndrome identified in referral versus unselected populations: systematic review and meta-analysis. Fertil Steril. 2016;2106(6):1510–1520.e2.
   PubMed Web of Science ®Google Scholar
• Lizneva D, Suturina L, Walker W, et al. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil Steril. 2016;106(1):6–15.
   PubMed Web of Science ®Google Scholar